Stockscreener 앱 받기
14.65
4.66%
-0.7539
전일 마감가:
$15.40
열려 있는:
$15.2
하루 거래량:
2.24M
Relative Volume:
0.86
시가총액:
$10.91B
수익:
$220.00K
순이익/손실:
$-921.61M
주가수익비율:
-11.79
EPS:
-1.2418
순현금흐름:
$-274.60M
1주 성능:
-10.97%
1개월 성능:
-16.06%
6개월 성능:
-44.93%
1년 성능:
-34.34%
1일 변동 폭
$14.43
$15.31
1주일 범위
$14.43
$16.78
52주 변동 폭
$14.43
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
14.65 | 11.46B | 220.00K | -921.61M | -274.60M | -1.2418 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.01 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.93 | 78.77B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
838.36 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.73 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.09 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Finviz
Summit Therapeutics (SMMT) Analyst Rating Update: January 30, 20 - GuruFocus
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA By Investing.com - Investing.com Canada
US regulator accepts Summit filing for ivonescimab combo - The Pharma Letter
Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway - Benzinga
Aug Gainers: Is Summit Therapeutics Inc impacted by rising rates2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
Summit Therapeutics (SMMT) Advances with FDA Filing for Cancer T - GuruFocus
Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab - marketscreener.com
Summit Therapeutics (SMMT) Gains After FDA Accepts Key Cancer Dr - GuruFocus
Summit Therapeutics’ Ivonescimab BLA Accepted by FDA - TipRanks
Summit spikes as lead asset undergoes FDA review - Seeking Alpha
Summit Therapeutics Inc FDA Accepts Ivonescimab BLA for NSCLC Treatment - TradingView
Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug - Investing.com
FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab - StreetInsider
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Yahoo Finance
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive - Finviz
Aug Retail: Can Summit Therapeutics Inc be the next market leaderPortfolio Risk Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Trading the Move, Not the Narrative: (SMMT) Edition - Stock Traders Daily
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a 100.75% Potential Upside in Biotech Investment - DirectorsTalk Interviews
Breakout Move: What is Summit Therapeutics Inc.’s TAM (Total Addressable Market)Options Play & Long-Term Safe Investment Ideas - mfd.ru
Will Ivonescimab’s FDA Filing and GSK Combo Trial Redefine Summit Therapeutics’ (SMMT) Core Narrative? - Sahm
Summit Therapeutics (NASDAQ:SMMT) Share Price Passes Above 50 Day Moving AverageHere's What Happened - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Nasdaq Index Biotech Research - Kalkine Media
Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? - Benzinga
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation - MSN
(SMMT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Is Summit Therapeutics (SMMT) Building a Durable Oncology Combination Platform With Ivonescimab’s Expanding Reach? - Sahm
Buyout Rumor: Will Summit Therapeutics Inc outperform the market in YEAR2025 Major Catalysts & Long-Term Growth Stock Strategies - baoquankhu1.vn
Summit Therapeutics Advances Ivonescimab Into Key Phase 3 Test in Metastatic Colorectal Cancer - TipRanks
Assessing Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Trial Collaboration - Sahm
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Summit Therapeutics PLC $SMMT Shares Purchased by APEIRON CAPITAL Ltd - MarketBeat
Summit Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Can Summit Therapeutics Inc. be the next market leaderBull Market Opportunities & Breakout Portfolio Performance - bollywoodhelpline.com
Rate Cut: Will Summit Therapeutics Inc benefit from AI trends2025 Macro Impact & Weekly Return Optimization Alerts - baoquankhu1.vn
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge - Yahoo Finance
Citizens reiterates Market Outperform rating on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 13.4%What's Next? - MarketBeat
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows - TechStock²
2 Biotech Stocks That Could Soar This Year - The Globe and Mail
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC - Business Wire
GSK Collaborates with Summit Therapeutics on Cancer Treatment Tr - GuruFocus
Summit Therapeutics Files Marketing Application for Lung Cancer Therapy - 富途牛牛
Summit Therapeutics (SMMT) Seeks FDA Approval for Innovative Lun - GuruFocus
Summit Therapeutics partners with GSK for cancer drug combination trial - StreetInsider
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) - Business Wire
Summit Therapeutics files FDA application for cancer drug ivonescimab - StreetInsider
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.25%
1.39%
자본화:
|
볼륨(24시간):